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Abstract 
Prospective studies concerning liver disease
in pediatric cystic fibrosis patients are scarce.
The present study aimed to describe the preva-
lence and clinical expression of cystic fibrosis
- related liver disease, in a cohort of 62 pedi-
atric  patients.  Descriptive  study,  resulting
from the prospective evaluation, between 1994
and 2009, of 62 pediatric patients (age <18
years) with cystic fibrosis. The follow-up proto-
col  included  a  clinical  assessment  every  2
months,  liver  function  tests  every  6  months
and annual liver ultrasonography. The cumula-
tive  prevalence  of  liver  disease  was  11.2%
(7/62 cases). All patients had ΔF508 mutation
and pancreatic insufficiency, none had meco-
nium ileus. The liver involvement became clin-
ically evident at a mean age of 8 years (3-15
years),  revealed  by  hepatomegaly  or
hepatosplenomegaly (3 cases) and/ or abnor-
malities  of  liver  function  tests  (3  cases)
changes of liver ultrasound (7 cases) with evi-
dence of portal hypertension (2 cases). Four
patients were submitted to liver biopsy; biliary
fibrosis was documented in one case, focal bil-
iary cirrhosis in 2 cases and multilobular cir-
rhosis in another case. Within a median 11.6
years  follow-up  period  (all  patients  under
UDCA therapy after liver disease diagnosis),
progression of liver disease was observed in 2
patients;  one  patient  developed  refractory
variceal bleeding and progressive hepatic fail-
ure, requiring liver transplant. The results of
the present study agree with those of previous
pediatric studies, further documenting clinical
expression  of  liver  disease  in  CF  patients,
which is usually detected in the first decade of
life and emphasize the contribution of ultra-
sound to early diagnosis of liver involvement.
Moreover, although advanced liver disease is a
relatively rare event, early isolated liver trans-
plantation may have to be considered at this
age group.
Introduction
When first described in 1938, cystic fibrosis
(CF) was invariably fatal during early child-
hood. Today, the average life expectancy is 35
years and therefore CF is no longer considered
an exclusively pediatric condition.1 Although
major  CF  morbidity  and  mortality  are  deter-
mined by pulmonary involvement, other mani-
festations of the disease have emerged, partic-
ularly the hepatobiliary involvement, in associ-
ation with improved survival related to early
multidisciplinary intervention.
The prevalence of CF-related liver disease,
currently considered the third cause of death
in CF,2 is difficult to assess because of the lack
of sensitive and specific markers. Although a
wide  prevalence  range  has  been  reported,
accordingly to the methodology and the charac-
teristics of the studied population, it is esti-
mated that liver disease occurs in about one
third of patients.3-5
Oral  therapy  with  ursodesoxycholic  acid
(UDCA), aiming to improve bile secretion, is
currently  the  only  available  pharmacological
intervention, although its impact on the natu-
ral history of liver disease and long-term effi-
cacy remains to be established.6,7 Liver trans-
plantation should be proposed in patients with
progressive  liver  failure  and/or  evidence  of
major portal hypertension in the absence of
significant  pulmonary  involvement.8,9 The
present  study  thus  aimed  to  describe  the
prevalence  and  clinical  expression  of  cystic
fibrosis - related liver disease, in a cohort of 62
pediatric patients prospectively followed in a
single pediatric reference CF centre, within a
median period of 11.6 years (seven CF cases
with  liver  involvement).  The  present  series
represents  the  first  report  from  our  country
concerning  CF-related  liver  disease,  further-
more including the first national case of liver
transplant for end-stage liver disease.
Materials and Methods
The analyzed cohort concerns 62 pediatric
patients prospectively followed in the CF cen-
tre  (Unit  of  Paediatric  Pneumology)  of
University Hospital de Santa Maria, from 1994
to 2009. Within the study period, no patient
has been transferred to the CF Adult Clinic.
The  diagnosis  of  CF  was  established  in  all
patients accordingly to conventional criteria,
including  two  positive  sweat  chloride  tests
(>60 mEq/L) and the identification of CFTR
gene described mutations. Pancreatic insuffi-
ciency  was  considered  when  fecal  elastase
level was lower than 200 mcg/g. The follow-up
protocol  included  clinical  evaluation  every  2
months, laboratory evaluation every 6 months
(alanine  aminotransferase-ALT,  aspartate
aminotransferase-AST, gamma-glutamyl trans  -
peptidase-GGT,  prothrombin  time  and  serum
albumin)  and  annual  liver  ultrasonography.
This follow-up protocol was integrated in the
routine of the CF clinic evaluation. The diag-
nosis of liver disease was considered if at least
one of the following was present in two consec-
utive evaluations in a period of 6 months: i)
Hepatomegaly (increased liver span with liver
edge palpable more than 2 cm below the costal
margin  on  the  mid-clavicular  line)  or
splenomegaly and/or; ii) Elevation of ALT, AST
or GGT> 1.5 the normal value (excluding the
periods  of  lung  exacerbation)  and/or;  iii)
Ultrasound abnormalities consistent with liver
involvement  according  to  conventional  crite-
ria,10 namely:  abnormalities  of  the  liver
parenchyma,  the  characteristics  of  the  liver
edge and the presence of periportal fibrosis.
Signs  of  portal  hypertension  (such  as
splenomegaly, enlarged portal vein diameter,
presence  of  collateral  vessels,  thickening  of
lesser omentum and reversal portal flow) were
also systematically reported if present. In the
patients  with  documented  liver  involvement,
other causes of chronic liver disease (alfa1-
antitrypsin deficiency, viral hepatitis B and C,
Wilson  disease  and  autoimmune  hepatitis)
were excluded. Upper digestive endoscopy for
detection  of  oesophageal  varices  was  per-
formed whenever evidence of portal hyperten-
sion was observed. Percutaneous liver biopsy
was performed in the first four cases, which
had evidence of more advanced liver disease.
All  patients  with  documented  liver  disease
were submitted to UDCA therapy, with an oral
daily dose of 20 mg/kg in two doses. Local insti-
tutional  Ethics  Committee  has  approved  the
study and informed consent to study inclusion
was obtained from all the parents. 
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Results
Liver involvement was documented in 7/62
patients (11.2%) and the mean age of liver dis-
ease diagnosis was 8 years (range 3-15 years).
The clinical characteristics of the 7 patients
are shown in the Table 1. The diagnosis of CF
in this cohort of patients was established at a
mean age of 3 years (range 3.5 months - 12
years), in the setting of recurrent pulmonary
infections and failure to thrive (five patients),
hepatosplenomegaly (one patient) and recur-
rent abdominal pain associated with intermit-
tent  diarrhea  (one  patient).  CF  genotypes
included the identification of ΔF508 mutation
in homozygosity in 6 patients and in heterozy-
gosity in 1 patient. All the patients had a posi-
tive sweat chloride test and severe pancreatic
insufficiency at the moment of the CF diagno-
sis and none was associated with meconium
ileus. Early lung colonization with polymicro-
bial flora was documented in four patients; the
remaining  had  colonization  with  a  single
agent (Staphylococcus aureus in two cases and
Pseudomonas  aeruginosa in  another  case).
Aspergillus  fumigatus was  identified  during
the  follow-up  period  in  two  patients.  Liver
involvement (clinical, laboratory and/or ultra-
sound  abnormalities)  became  clinically  evi-
dent at a median age of 7 years, occurring in
the first decade of life in five children (Table
2). The more severe patient (case 4) had an
early presentation at 3 years of age. Clinical
signs  of  liver  disease  were  present  in  only
three  patients,  including  isolated
hepatomegaly in one and hepatosplenomegaly
in the remaining two. Biochemical abnormali-
ties (raised ALT, AST and /or GGT) were pres-
ent in six patients (three with AST/ALT >1.5
upper limit). In patient 7, liver enzymes were
persistently  normal.  With  the  exception  of
patient  4,  submitted  to  liver  transplant,  no
abnormalities in the liver synthesis tests have
been detected. All patients showed ultrasound
changes. The most frequently identified abnor-
mality was heterogeneous echogenicity of the
hepatic  parenchyma  (6/7),  with  nodularity
additionally  present  in  2/7  patients,  nodular
liver edge in 1/7 patients and signs of portal
hypertension in 2/7 patients (with inversion of
the portal vein and collateral vessels flow in
case  4).  Patient  6  had  homogeneous
echogenicity of the hepatic parenchyma. 
Three from four patients submitted to upper
digestive  endoscopy  revealed  oesophageal
varices grade I to III; two of them also had clin-
ical  criteria  (thrombocytopenia  and
splenomegaly) and/or ultrasound signs of por-
tal hypertension. These two patients were sub-
mitted  to  prophylactic  elastic  ligature.  Liver
biopsy was performed in four patients, docu-
menting the presence of focal biliary cirrhosis
(2/7),  multilobular  biliary  cirrhosis  (1/7)
(these three patients had ultrasound evidence
of more advanced hepatic disease) and of focal
biliary  fibrosis  (1/7).  All  the  patients  were
maintained  under  UDCA  therapy  since  the
diagnosis of liver disease. During a mean fol-
low-up period of 7 years (range 3-15 years),
Aricle
Liver disease manifestations on clinical presentation. 
Case Onset of liver  Physical  Laboratory findings  Hepatobiliary Upper Liver
disease, years findings (U/L)** ultrasound digestive  histology
endoscopy
1 5  Hepatomegaly AST 141 Heterogeneous No varices Focal biliary  
ALT 96 echogenicity,  cirrhosis  
GGT 87 nodularity
2 9  No abnormalities AST 41 Heterogeneous Oesophageal varices  Moderate biliary 
ALT 49 echogenicity grade I fibrosis 
GGT 40
3 12 Hepatomegaly AST 80 Heterogeneous Oesophageal varices Focal biliary  
Splenomegaly ALT 84 echogenicity, grade I/II cirrhosis 
GGT 114 nodular liver edge,
reverse flow on portal vein
4* 3 Hepatomegaly AST 39 Heterogeneous Oesophageal varices  Multilobular 
Splenomegaly ALT 41 echogenicity, grade II/III biliary cirrhosis
GGT 33 nodularity,
collateral circulation
57 No abnormalities AST 40 Heterogeneous --
ALT 30 echogenicity
GGT 35
65 No abnormalities AST 48 Heterogeneous  --
ALT 43 echogenicity
GGT 24
7 15 No abnormalities AST 23 Heterogeneous --
ALT 25 echogenicity
GGT 14
*Patient submitted to liver transplantation; **Reference levels: AST/ ALT: 35/45 IU/L, y-GT: 38 IU/L.
Table 1. Characteristics of the patients with liver disease.
Case Gender Age at Genotype Fecal elasase  Pulmonary
CF diagnosis,  (mcg/g) Colonization
years
1M 0,3 ΔF508/ΔF508 27 SA, PA
2M 3 ΔF508/ΔF508 17 PA, BC, AF
3M 12 ΔF508/S549C 25 SA
4F 0,4 ΔF508/ΔF508 20 SA, PA, BC, AF
5M 1,4 ΔF508/ΔF508 8 PA, BC
6F 5 ΔF508/ΔF508 1 PA
7F 1 ΔF508/ΔF508 26 SA
CF, Cystic fibrosis; SA, Staphylococcus aureus, PA, Pseudomonas aeruginosa, BC, Burkholderia cepacia, AF, Aspergillus fumigatus).[Pediatric Reports 2011; 3:e21] [page 89]
progression of liver disease was verified in two
patients. Patient 1 developed splenomegaly as
well  as  ultrasound  signs  of  portal  hyperten-
sion,  associated  with  the  presence  of
oesophageal  varices,  without  variceal  bleed-
ing. Patient 4 developed severe portal hyper-
tension  (first  variceal  bleeding  at  age  of  5
years), complicated by progressive hepatic fail-
ure  plus  refractory  variceal  bleeding  and
underwent liver transplant at age of 8 years.
Under  conventional  immunosuppression,  a
good outcome has been observed so far, includ-
ing normality of the liver function tests, as well
as pulmonary improvement (absence of hospi-
tal admissions and improvement on the lung
function  tests)  and  significant  catch-up
growth.
Discussion
Very few prospective studies have previous-
ly evaluated the occurrence of CF-related liver
disease at pediatric age. In this single centre
study (first national study of liver involvement
in  CF-related  liver  disease),  evaluating  62
pediatric patients prospectively followed dur-
ing a median 11.6 years follow-up period, we
aimed to report the prevalence and the clinical
profile  of  CF-related  liver  disease.  In  our
cohort, the prevalence of liver disease associ-
ated to CF assessed according to the current
recommended  criteria,  was  relatively  lower
(11.2%), as compared to the prevalence of 27%
and of 35% reported in other similarly prospec-
tive studies.5,11 Additionally to the use of non-
invasive tests, this might be partially explained
by  a  lower  median  follow-up  period  in  our
study, potentially contributing to underestima-
tion of the true prevalence of CF-related liver
disease.
The reported prevalence of liver disease in
CF pediatric patients has revealed a wide vari-
ability,3,5,11,12 greatly influenced by the study
design (retrospective/prospective) and by the
selected  diagnostic  criteria.  In  fact,  the
absence  of  diagnostic  markers  sufficiently
sensitive and specific, is a major recognized
limitation and the use of the current standard
criteria for evaluation of liver disease in this
setting,  probably  underestimates  its  true
prevalence.  Furthermore,  liver  biopsy,  which
should be the election technique to diagnose
liver disease, has been considered of question-
able interest due to its invasivity and the het-
erogeneous distribution of the hepatic lesions
in CF.4Some studies have suggested the poten-
tial  association  between  the  development  of
liver disease and the previous history of meco-
nium  ileus  and  the  presence  of  pancreatic
insufficiency.5 In our series, no case had previ-
ous history of meconium ileus, but severe pan-
creatic insufficiency was present in all cases at
the diagnosis, accordingly to ΔF508 genotype.
The  mean  age  of  liver  disease  diagnosis,  8
years, is in agreement with previous reports
describing a characteristic presentation in the
first two decades of life, with a peak at prepu-
berty  age.3 Hepatomegaly  or  hepatosplen  -
omegaly was detected in only 3/7 cases, fur-
thermore confirming that the absence of phys-
ical  signs  does  not  necessarily  exclude  the
presence  of  potentially  advanced  liver  dis-
ease.5,11 Moreover, an intermittent elevation of
the liver enzymes due to pulmonary exacerba-
tions requiring antibiotic therapy is a common
occurrence in these patients. For this reason,
an enzyme increase for a period superior to 6
months  outside  the  pulmonary  exacerbation
period is usually a required criterion for detec-
tion  of  liver  involvement.13 Similarly  as
Colombo et al.,5 reporting a frequency of 56%
of  patients  with  raised  liver  enzymes,  we
noticed, in our series (using identical diagnos-
tic criteria), an increase in liver enzymes in
42.5%  of  the  patients.(3/7  cases)  As  pre-
dictable,  the  liver  synthesis  parameters
remained preserved, with the exception of the
case that progressed to end-stage liver disease.
On the other hand, we also observed, as usual-
ly recognized, that the liver enzymes can be
normal or just slightly raised in patients with
clinically evident disease, as it was the case of
patient 4. Our results clearly emphasize the
role  of  ultrasonography  in  the  screening  of
liver  disease  in  this  setting,  as  it  detected
abnormalities in 4/7 children without laborato-
ry or physical findings, with three of them hav-
ing advanced liver disease. Given the low sen-
sitivity and specificity of other diagnostic tests,
ultrasound is a non-invasive tool of relevance
in the early assessment of liver disease in the
CF,  if  performed  by  an  experienced  radiolo-
gist.14,15 The relevance of an early diagnosis of
the  liver  involvement  has  also  therapeutic
implications, since early therapy with UDCA is
recommended. The available evidence shows
an  improvement  of  the  biliary  secretion,
reflected  by  persistent  normalization  of
cholestasis  markers  and  histology  improve-
ment.6,7 Although in our series all cases have
been submitted to treatment with UDCA since
the diagnosis of liver disease, it is difficult to
evaluate objectively its contribution to the nat-
ural history of the disease. The morbidity asso-
ciated  with  liver  involvement  in  CF  arises
mainly from complications of portal hyperten-
sion, including upper gastrointestinal bleeding
and hypersplenism. The management of portal
hypertension is one of the most problematic
and  controversial  aspects  in  CF  patients.
Several therapeutic modalities have been rec-
ommended,  including  conventional  support
therapy (variceal banding or sclerosis), porto-
systemic shunts,16,17 or other alternatives such
as splenectomy or selective splenic emboliza-
tion.18-20The results of these therapeutic inter-
ventions are of difficult evaluation given the
reduced  number  of  patients  included  in  the
available reports. Patient 4 in our series, con-
cerning a child with end-stage liver disease,
which required liver transplant, is illustrative
of  the  therapeutic  dilemmas  in  this  clinical
setting.  Refractory  bleeding  secondary  to
oesophageal varices, associated with progres-
sive deterioration of liver function in the set-
ting  of  preserved  lung  function,  determined
the choice of an isolated liver transplant. The
potential  indication  to  perform  a  porto-sys-
temic shunt at an earlier stage has been ques-
tioned by several authors, as a previous sur-
gery in the portal area might determine techni-
cal  constraints  to  liver  transplantion.  Liver
transplantion should be considered in patients
with progressive liver failure and/or evidence
of major portal hypertension, in the absence of
significant  pulmonary  involvement  (forced
expiratory volume at 1 second >50%).8,9 The
reported survival rate one year after the liver
transplant  has  been  of  approximately  80%
(similarly  to  the  reported  survival  in  other
indications for liver transplant)8 and in most
cases it is associated with evident benefit in
the  pulmonary  function,  in  the  nutritional
state and in the quality of life, as illustrated by
our  patient.21-23 In  conclusion,  the  present
series, representing a first national report con-
cerning liver involvement in the setting of CF,
aimed to further contribute to the knowledge
of  its  prevalence  and  clinical  expression  at
pediatric  age.  Our  data  confirmed  that
although advanced liver disease is a relatively
rare event at this age group, early isolated liver
transplantation might have to be considered.
Emerging evidence from novel studies evaluat-
ing  putative  polymorphisms  in  genes  other
than the cystic fibrosis transmembrane con-
ductance regulator (CFTR) gene, may further
elucidate CF-related liver disease pathogene-
sis.24 It is predictable that liver disease occur-
ring  both  at  childhood  and    adulthood,  will
have  an  increasing  impact  on  survival  and
quality of life of these patients, emphasizing
the  importance  of  its  early  recognition  and
intervention, as well as of an adequate coordi-
nation  between  the  Pediatric  and  Adult  CF
teams in this setting.    
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